BR112015001390A2 - vacina de proteína de fusão multimérica e imunoterápicos - Google Patents

vacina de proteína de fusão multimérica e imunoterápicos

Info

Publication number
BR112015001390A2
BR112015001390A2 BR112015001390A BR112015001390A BR112015001390A2 BR 112015001390 A2 BR112015001390 A2 BR 112015001390A2 BR 112015001390 A BR112015001390 A BR 112015001390A BR 112015001390 A BR112015001390 A BR 112015001390A BR 112015001390 A2 BR112015001390 A2 BR 112015001390A2
Authority
BR
Brazil
Prior art keywords
fusion protein
proteins
protein
vaccine
fusion
Prior art date
Application number
BR112015001390A
Other languages
English (en)
Other versions
BR112015001390B1 (pt
Inventor
M Snapper Clifford
J Mond James
Cui Xinle
Original Assignee
Henry M Jackson Found Advancement Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Found Advancement Military Medicine Inc filed Critical Henry M Jackson Found Advancement Military Medicine Inc
Publication of BR112015001390A2 publication Critical patent/BR112015001390A2/pt
Publication of BR112015001390B1 publication Critical patent/BR112015001390B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

resumo patente de invenção: "vacina de proteína de fusão multimérica e imunoterápicos". a presente invenção proporciona proteínas de fusão que incorporam mecanismos únicos para multimerizar antígenos para melhorar a sua imunogenicidade. as proteínas de fusão compreendem pelo menos dois antígenos, ou outras proteínas relacionadas a vacinas, separadas por uma sequência de ligante e um domínio de oligomerização. quando expressa, a proteína de fusão forma um complexo proteico multimérico. esta abordagem pode ser utilizada para multimerizar um único antígeno/proteína ou para criar multímeros compreendendo dois ou mais diferentes antígenos/proteínas. também proporcionados são ácidos nucleicos que codificam as proteínas de fusão, ainda um outro aspecto refere-se a métodos para induzir ou suprimir uma resposta imune em um indivíduo por administração ao indivíduo de uma composição de vacina compreendendo uma proteína de fusão ou de ácido nucleico que codifica a proteína de fusão, opcionalmente sem a utilização de um adjuvante.
BR112015001390-2A 2012-07-26 2013-07-26 Proteína de fusão, ácido nucleico isolado e uso de uma composição de vacina BR112015001390B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261675948P 2012-07-26 2012-07-26
US61/675,948 2012-07-26
PCT/US2013/052270 WO2014018858A2 (en) 2012-07-26 2013-07-26 Multimeric fusion protein vaccine and immunotherapeutic

Publications (2)

Publication Number Publication Date
BR112015001390A2 true BR112015001390A2 (pt) 2017-09-26
BR112015001390B1 BR112015001390B1 (pt) 2024-04-30

Family

ID=49997985

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015001390-2A BR112015001390B1 (pt) 2012-07-26 2013-07-26 Proteína de fusão, ácido nucleico isolado e uso de uma composição de vacina

Country Status (7)

Country Link
US (2) US9962436B2 (pt)
EP (1) EP2877205A4 (pt)
JP (2) JP6373836B2 (pt)
AU (2) AU2013295647B2 (pt)
BR (1) BR112015001390B1 (pt)
CA (1) CA2878427A1 (pt)
WO (1) WO2014018858A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220332772A1 (en) * 2010-11-15 2022-10-20 The Board Of Trustees Of The University Of Illinois Vaccine and methods for detecting and preventing filariasis
US10016494B2 (en) 2014-02-07 2018-07-10 Valorisation-Hsj, Limited Partnership Antigenic epitopes from EBV gp350/220 and uses thereof
US10314906B2 (en) 2015-03-18 2019-06-11 University Of Massachusetts Virus-like particle compositions and vaccines against Epstein-Barr virus infection and disease
WO2017011380A1 (en) * 2015-07-14 2017-01-19 The Board Of Trustees Of The University Of Illinois Vaccine and methods for detecting and preventing filariasis
WO2017172853A1 (en) * 2016-03-30 2017-10-05 Ab Biosciences, Inc. Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use
WO2018074558A1 (ja) * 2016-10-23 2018-04-26 デンカ株式会社 複合ポリペプチド単量体、細胞浸透機能を有する当該複合ポリペプチドの単量体の会合体、及び、当該会合体を有効成分とする皮下、皮内、経皮又は筋肉内投与用ノロウイルスコンポーネントワクチン
WO2018115305A1 (en) * 2016-12-22 2018-06-28 Leibniz-Institut für Pflanzengenetik Und Kulturpflanzenforschung (IPK) Oligomeric vaccines from plants by s-tag-s-protein fusions
WO2018140733A1 (en) * 2017-01-27 2018-08-02 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
US11793873B2 (en) 2017-05-10 2023-10-24 University Of Massachusetts Bivalent dengue/hepatitis B vaccines
GB2568550B (en) * 2017-11-21 2021-06-30 Univ Cape Town Method of synthesising 6-deoxy-6-amino-ß-d-glucopyranoside-containing polymers
EP3730620A4 (en) * 2017-12-21 2022-01-05 Green Biomed, Inc. CROSS-IMMUNIZATION ANTIGENIC VACCINE AND PROCESS FOR PREPARATION
KR20210018205A (ko) 2018-04-03 2021-02-17 사노피 항원성 OspA 폴리펩타이드
JP2021519596A (ja) 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ フェリチンタンパク質
JP2021519598A (ja) * 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ 抗原性エプスタインバーウイルスポリペプチド
WO2019213550A1 (en) * 2018-05-03 2019-11-07 Duke University Vaccine compositions and methods for enhanced antigen-specific vaccination
CN111658770A (zh) * 2019-03-05 2020-09-15 周文云 P14.7蛋白质及其作为疫苗佐剂的用途
WO2021002855A1 (en) * 2019-07-02 2021-01-07 Virago Vax Inc. Mammary tumor virus vaccine
AU2021287508B2 (en) * 2020-06-09 2023-11-09 Km Biologics Co., Ltd. Fusion protein of pentamer and gB of cytomegalovirus, and vaccine containing said fusion protein
CN111662390A (zh) * 2020-06-17 2020-09-15 天康生物(上海)有限公司 禽流感HA-Fd融合蛋白及其制备方法和疫苗
JPWO2022085648A1 (pt) * 2020-10-19 2022-04-28
WO2022238381A2 (en) * 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunotherapy constructs for treatment of disease
CA3212784A1 (en) * 2021-05-10 2022-11-17 Agnete Brunsvik Fredriksen Tolerance-inducing constructs and compositions and their use for the treatment of immune disorders
WO2023240225A1 (en) * 2022-06-09 2023-12-14 The University Of North Carolina At Chapel Hill Constitutively active polymeric sting mimics for antitumor immunity

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4744984A (en) 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
CA2146559A1 (en) 1992-10-23 1994-05-11 Melanie K. Spriggs Methods of preparing soluble, oligomeric proteins
GB9615726D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Anti-viral agent 11
KR20010022452A (ko) 1997-07-31 2001-03-15 추후제출 플라비바이러스 감염에 대한 재조합 다이머형 엔벨롭 백신
JP5138844B2 (ja) * 1998-06-12 2013-02-06 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド 抗原およびＥＢＶＧｐ３５０／２２０の受容体の同時刺激によるＢ細胞活性化および免疫グロブリン分泌の増強
US7144991B2 (en) * 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
IL147270A0 (en) 1999-07-02 2002-08-14 Genentech Inc Fusion peptides comprising a peptide ligand domain and a multimerization domain
WO2001019958A2 (en) 1999-09-17 2001-03-22 Dana-Farber Cancer Institute, Inc. Stabilized soluble glycoprotein trimers
DE60232577D1 (de) 2001-01-18 2009-07-23 Vlaams Interuniv Inst Biotech Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
GB0113798D0 (en) 2001-06-06 2001-07-25 Chiron Spa Antigens and vectors for vaccination
WO2004094613A2 (en) * 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
ATE493437T1 (de) * 2004-07-23 2011-01-15 Novartis Vaccines & Diagnostic Polypeptide für die oligomerisierung von antigenen
GB0605735D0 (en) * 2006-03-22 2006-05-03 Immunobiology Ltd Composition and method for mediating an immune response
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
AU2008214344B2 (en) 2007-02-08 2012-06-07 Merck Sharp & Dohme Corp. Antibodies specific for Dkk-1
ES2372359T3 (es) 2007-04-20 2012-01-19 F. Hoffmann-La Roche Ag Detección de infecciones primarias por patógenos.
CA2705373A1 (en) * 2007-11-12 2009-08-20 The Henry M. Jackson Foundation For The Advancement Of Military Medicine , Inc. Hiv-1 envelope glycoprotein oligomer and methods of use
DK2257307T3 (en) 2008-02-20 2018-08-20 Glaxosmithkline Biologicals Sa BIOCONJUGATES MANUFACTURED FROM RECOMBINANT N-Glycosylated PROTEINS FROM PROCARYOTIC CELLS
EP2313108A4 (en) 2008-06-30 2013-06-12 Us Army As Represented By The Secretary Of The Army ANTIPALUDE VACCINE OF SELF-ASSEMBLED POLYPEPTIDE NANOPARTICLES
WO2010057501A1 (en) 2008-11-21 2010-05-27 Københavns Universitet (University Of Copenhagen) Priming of an immune response
JP6339366B2 (ja) 2010-05-06 2018-06-06 グリコヴァキシン アーゲー 莢膜グラム陽性菌のバイオコンジュゲートワクチン

Also Published As

Publication number Publication date
US20180303931A1 (en) 2018-10-25
US9962436B2 (en) 2018-05-08
US10821173B2 (en) 2020-11-03
WO2014018858A3 (en) 2015-04-16
JP6373836B2 (ja) 2018-08-15
WO2014018858A2 (en) 2014-01-30
JP2015530369A (ja) 2015-10-15
AU2013295647A1 (en) 2015-01-29
US20150174237A1 (en) 2015-06-25
JP2018138581A (ja) 2018-09-06
EP2877205A2 (en) 2015-06-03
AU2018203170A1 (en) 2018-05-24
EP2877205A4 (en) 2016-04-06
BR112015001390B1 (pt) 2024-04-30
AU2018203170B2 (en) 2020-03-26
AU2013295647B2 (en) 2018-02-08
CA2878427A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
BR112015001390A2 (pt) vacina de proteína de fusão multimérica e imunoterápicos
BR112018072485A2 (pt) proteínas de ligação biespecíficas e usos das mesmas
PH12017501287A1 (en) A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
BR112014031327A2 (pt) ácidos nucleicos para o tratamento de alergias
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
WO2016107818A8 (en) Compositions and methods for protein glycosylation
BR112015017619A2 (pt) formulação líquida, uso de uma formulação, e, kit
EA201391240A1 (ru) Слитые белки и комбинированные вакцины, содержащие белок е и пилин а haemophilus influenza
BR112015022978A2 (pt) agente de ligação biespecífico, seu método de produção composição farmacêutica, proteína de fusão, uso, sequência de ácido nucleico, vetor, célula hospedeira, método de matar células tumorais e de inibir o crescimento tumoral
BR112013032251A2 (pt) composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
BR112019021824A2 (pt) Vacinas contra a malária e anticorpos de ligação a esporozoítos de plasmódio
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
MX2019003615A (es) Proteina central y proteina del antigeno de superficie del virus de la hepatitis b y vacunas que comprenden estas.
BR112014012460A2 (pt) proteínas recombinantes e seus usos terapêuticos
NZ766005A (en) Factor h binding protein variants and methods of use thereof
BR112015000585A8 (pt) método para preparar uma cepa mutante de mycoplasma hyopneumoniae, vetores, cepa mutante, vacina, kit de vacinação e usos do vetor e da cepa mutante
MX2015000754A (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
JP2015529677A5 (pt)
BR112013025294A2 (pt) moléculas de ligação biespecífica ligando a dll4 e ang2
RU2015106916A (ru) Полипептиды clostridium difficile в виде вакцины
JP2016520534A5 (pt)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/07/2013, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.